In vitro safety “clinical trial” of the cardiac liability of drug polytherapy
Abstract Only a handful of US Food and Drug Administration (FDA) Emergency Use Authorizations exist for drug and biologic therapeutics that treat severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection. Potential therapeutics include repurposed drugs, some with cardiac liabilities. We...
Main Authors: | Bérénice Charrez, Verena Charwat, Brian Siemons, Henrik Finsberg, Evan W. Miller, Andrew G. Edwards, Kevin E. Healy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13038 |
Similar Items
-
Isochoric supercooled preservation and revival of human cardiac microtissues
by: Matthew J. Powell-Palm, et al.
Published: (2021-09-01) -
Improved Computational Identification of Drug Response Using Optical Measurements of Human Stem Cell Derived Cardiomyocytes in Microphysiological Systems
by: Karoline Horgmo Jæger, et al.
Published: (2020-02-01) -
Rational Polytherapy with Antiepileptic Drugs
by: Jong Woo Lee, et al.
Published: (2010-07-01) -
Polytherapy and drug interactions in elderly
by: Hima Bindu Gujjarlamudi
Published: (2016-01-01) -
Rational polytherapy in the treatment of cholinergic seizures
by: Jerome Niquet, et al.
Published: (2020-01-01)